This work was supported by the Italian Ministry of Instruction, University and Research (MIUR) (Accordi di Programma 2011: RBAP11YS7K_001 [HIRMA], Bandiera InterOmics Protocollo PB05 1°), and by Aviralia Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Handling Editor: Vincent Wong

Read the full text

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Abstract

Background & Aims

Despite the excellent efficacy of direct-acting antivirals (DAA) reported in clinical trials, virological failures can occur, often associated with the development of resistance-associated substitutions (RASs). This study aimed to characterize the presence of clinically relevant RASs to all classes in real-life DAA failures.

Methods

Of the 200 virological failures that were analyzed in 197 DAA-treated patients, 89 with pegylated-interferon+ribavirin (PegIFN+RBV) and 111 without (HCV-1a/1b/1g/2/3/4=58/83/1/6/24/25; 56.8% treatment experienced; 65.5% cirrhotic) were observed. Sanger sequencing of NS3/NS5A/NS5B was performed by home-made protocols, at failure (N=200) and whenever possible at baseline (N=70).

Results

The majority of the virological failures were relapsers (57.0%), 22.5% breakthroughs, 20.5% non-responders. RAS prevalence varied according to IFN/RBV use, DAA class, failure type and HCV genotype/subtype. It was 73.0% in IFN group vs 49.5% in IFN free, with the highest prevalence of NS5A-RASs (96.1%), compared to NS3-RASs (75.9% with IFN, 70.5% without) and NS5B-RASs (66.6% with IFN, 20.4% without, in sofosbuvir failures). In the IFN-free group, RASs were higher in breakthrough/non-responders than in relapsers (90.5% vs 40.0%, P<.001). Interestingly, 57.1% of DAA IFN-free non-responders had a misclassified genotype, and 3/4 sofosbuvir breakthroughs showed the major-RAS-S282T, while RAS-L159F was frequently found in sofosbuvir relapsers (18.2%). Notably, 9.0% of patients showed also extra target RASs, and 47.4% of patients treated with ≥2 DAA classes showed multiclass resistance, including 11/11 NS3+NS5A failures. Furthermore, 20.0% of patients had baseline-RASs, which were always confirmed at failure.

Conclusions

In our failure setting, RAS prevalence was remarkably high in all genes, with a partial exception for NS5B, whose limited resistance is still higher than previously reported. This multiclass resistance advocates for HCV resistance testing at failure, in all three genes for the best second-line therapeutic tailoring.

Supporting Information

References

1 EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017; 66: 153–194.
Google Scholar
2 Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C. http://www.hcvguidelines.org. Accessed September 16, 2016.
Google Scholar
3Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology. 2016; 63: 1430–1441.
10.1002/hep.28473
CAS PubMed Web of Science® Google Scholar
4Krishnan P, Tripathi R, Schnell G, et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother. 2015; 59: 5445–5454.
10.1128/AAC.00998-15
CAS PubMed Web of Science® Google Scholar
5Kwo P, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in HCV genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3. Randomized study. Hepatology. 2016; 64: 370–380.
10.1002/hep.28467
CAS PubMed Web of Science® Google Scholar
6Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology. 2015; 64: 360–369.
10.1002/hep.28422
CAS Web of Science® Google Scholar
7Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016; 63: 1493–1505.
10.1002/hep.28446
CAS PubMed Web of Science® Google Scholar
8Pawlotsky JM, Hepatitis C. Virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016; 151: 70–86.
10.1053/j.gastro.2016.04.003
CAS PubMed Web of Science® Google Scholar
9Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med. 2010; 2: 30ra32.
10.1126/scitranslmed.3000544
CAS PubMed Web of Science® Google Scholar
10Bartels DJ, Sullivan JC, Zhang EZ, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol. 2013; 87: 1544–1553.
10.1128/JVI.02294-12
CAS PubMed Web of Science® Google Scholar
11Svarovskaia ES, Zeuzem S, Hedskog C, et al. Prevalence of pretreatment NS5A and NS5B resistance-associated variants and genetic variation within HCV subtypes across different countries/gilead-study. J Hepatol. 2015; 62: S679.
10.1016/S0168-8278(15)31097-7
Web of Science® Google Scholar
12Yoshimi S, Imamura M, Murakami E, et al. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J Med Virol. 2015; 87: 1913–1920.
10.1002/jmv.24255
CAS PubMed Web of Science® Google Scholar
13Krishnan P, Tripathi R, Schnell G, et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens. J Hepatol. 2015; 62: S220.
10.1016/S0168-8278(15)30071-4
Web of Science® Google Scholar
14Dvory-Sobol H, Wyles D, Ouyang W, et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. J Hepatol. 2015; 62: S221.
10.1016/S0168-8278(15)30073-8
Web of Science® Google Scholar
15Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016; 64: 486–504.
10.1016/j.jhep.2015.09.011
PubMed Web of Science® Google Scholar
16Lawitz E, Flamm S, Yang JC, et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. J Hepatol. 2015; 62: S192.
10.1016/S0168-8278(15)30012-X
Web of Science® Google Scholar
17Gane EJ, Shiffman ML, Etzkorn K, et al. Sofosbuvir/velpatasvir in combination with ribavirin for 24 weeks is effective retreatment for patients who failed prior NS5A-containing DAA regimens: results of the retreatment study. J Hepatol. 2016; 64: S147.
10.1016/S0168-8278(16)00037-4
Web of Science® Google Scholar
18Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016; 151: 501–512.
10.1053/j.gastro.2016.06.002
CAS PubMed Web of Science® Google Scholar
19Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015; 163: 1–13.
10.7326/M15-0785
PubMed Web of Science® Google Scholar
20Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, Elbasvir, and Ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis. 2016; 62: 32–36.
10.1093/cid/civ722
CAS PubMed Web of Science® Google Scholar
21Hezode C, Chevaliez S, Scoazec G, et al. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. Hepatology. 2016; 63: 1809–1816.
10.1002/hep.28491
CAS PubMed Web of Science® Google Scholar
22Vermehren J, Susser S, Dietz J, et al. Retreatment of patients who failed DAA-combination therapies: Real-world experience from a large hepatitis C resistance database. J Hepatol. 2016; 64: S188.
10.1016/S0168-8278(16)00128-8
Web of Science® Google Scholar
23Lontok E, Harrington P, Howe A, et al. Hepatitis C Virus drug resistance-associated substitutions: state of the art summary. Hepatology. 2015; 62: 1623–1632.
10.1002/hep.27934
PubMed Web of Science® Google Scholar
24 European Association for Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015; 63: 199–236.
10.1016/j.jhep.2015.03.025
PubMed Web of Science® Google Scholar
25Craxi A, Perno CF, Vigano M, Ceccherini-Silberstein F, Petta S. From current status to optimization of HCV treatment: recommendations from an expert panel. Dig Liver Dis. 2016; 48: 995–1005.
10.1016/j.dld.2016.06.004
PubMed Web of Science® Google Scholar
26Buti M, Riveiro-Barciela M, Esteban R. Management of direct-acting antiviral agent failures. J Hepatol. 2015; 63: 1511–1522.
10.1016/j.jhep.2015.08.010
PubMed Web of Science® Google Scholar
27Ceccherini SF, Di MV, Aragri M, Ciotti M, Cento V, Perno CF. Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents. Hepatology. 2015; 63: 1058–1059.
10.1002/hep.27895
PubMed Web of Science® Google Scholar
28Di Maio VC, Cento V, Di Paolo D, et al. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. J Antimicrob Chemother. 2016; 71: 739–750.
10.1093/jac/dkv403
CAS PubMed Web of Science® Google Scholar
29Barnard RJ, Howe JA, Ogert RA, et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology. 2013; 444: 329–336.
10.1016/j.virol.2013.06.029
CAS PubMed Web of Science® Google Scholar
30Kieffer TL, De MS, Bartels DJ, et al. Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS ONE. 2012; 7: e34372.
10.1371/journal.pone.0034372
CAS PubMed Web of Science® Google Scholar
31Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010; 138: 447–462.
10.1053/j.gastro.2009.11.055
CAS PubMed Web of Science® Google Scholar
32Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014; 59: 1666–1674.
10.1093/cid/ciu697
CAS PubMed Web of Science® Google Scholar
33Black S, Pak I, Ingravallo P, et al. Resistance analysis of virologic failures in hepatitis C genotype 1-infected patients treated with Grazoprevir + Elbasvir ± Ribavirin: the C-WORTHY study. J Hepatol. 2015; 62: S620.
10.1016/S0168-8278(15)31094-1
Google Scholar
34Hepatitis C. Guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015; 62: 932–954.
10.1002/hep.27950
PubMed Web of Science® Google Scholar
35Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014; 383: 515–523.
10.1016/S0140-6736(13)62121-2
CAS PubMed Web of Science® Google Scholar
36Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013; 368: 1867–1877.
10.1056/NEJMoa1214854
CAS PubMed Web of Science® Google Scholar
37Andre-Garnier E, Ribeyrol O, Gournay J, et al. Emergence of HCV resistance-associated variants in patients failing sofosbuvir-based regimens: an observational cohort. Antivir Ther. 2016; 21: 611–619.
10.3851/IMP3053
CAS PubMed Web of Science® Google Scholar
38Svarovskaia ES, Gane E, Dvory-Sobol H, et al. L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions. J Infect Dis. 2016; 213: 1240–1247.
10.1093/infdis/jiv564
CAS PubMed Web of Science® Google Scholar
39Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology. 2015; 61: 56–65.
10.1002/hep.27375
CAS PubMed Web of Science® Google Scholar
40Hezode C, Fourati S, Scoazec G, et al. Retreatment of HCV DAA failures: HCV infection may be incurable. J Hepatol. 2016; 64: S400.
10.1016/S0168-8278(16)00630-9
Google Scholar
41Poordad F, Bennett M, Sepe TE, et al. Ombitasvir/Paritaprevir/r, Dasabuvir, and sofosbuvir treatment of patients with HCV genotype 1-infection who failed a prior course of DAA therapy: the QUARTZ-I study. J Hepatol. 2016; 64: S767.
10.1016/S0168-8278(16)01496-3
Web of Science® Google Scholar

Citing Literature

Volume37, Issue4

April 2017

Pages 514-528

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

Abstract

Background & Aims

Methods

Results

Conclusions

Supporting Information

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

Abstract

Background & Aims

Methods

Results

Conclusions

Supporting Information

References

Citing Literature

References

Related

Information